WINTON GROUP Ltd Buys Shares of 67,005 Fennec Pharmaceuticals Inc (NASDAQ:FENC)

WINTON GROUP Ltd bought a new stake in Fennec Pharmaceuticals Inc (NASDAQ:FENC) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 67,005 shares of the company’s stock, valued at approximately $409,000. WINTON GROUP Ltd owned about 0.25% of Fennec Pharmaceuticals at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Acadian Asset Management LLC acquired a new stake in shares of Fennec Pharmaceuticals during the second quarter worth about $49,000. Jump Financial LLC acquired a new position in Fennec Pharmaceuticals in the fourth quarter valued at approximately $158,000. Rhumbline Advisers lifted its holdings in Fennec Pharmaceuticals by 44.7% in the second quarter. Rhumbline Advisers now owns 29,110 shares of the company’s stock valued at $178,000 after acquiring an additional 8,987 shares during the period. BNP Paribas Financial Markets raised its stake in shares of Fennec Pharmaceuticals by 67.7% during the 1st quarter. BNP Paribas Financial Markets now owns 32,769 shares of the company’s stock worth $364,000 after buying an additional 13,223 shares during the period. Finally, Russell Investments Group Ltd. raised its stake in shares of Fennec Pharmaceuticals by 71,275.0% during the 1st quarter. Russell Investments Group Ltd. now owns 34,260 shares of the company’s stock worth $381,000 after buying an additional 34,212 shares during the period. Hedge funds and other institutional investors own 55.51% of the company’s stock.

Fennec Pharmaceuticals Stock Down 0.8 %

Shares of NASDAQ:FENC opened at $5.22 on Thursday. Fennec Pharmaceuticals Inc has a 52-week low of $5.00 and a 52-week high of $11.92. The business has a fifty day moving average of $5.86 and a two-hundred day moving average of $7.59. The stock has a market cap of $142.65 million, a P/E ratio of 174.00 and a beta of 0.26. The company has a quick ratio of 7.75, a current ratio of 8.02 and a debt-to-equity ratio of 9.86.

Fennec Pharmaceuticals (NASDAQ:FENC) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of $0.06 by ($0.26). Fennec Pharmaceuticals had a net margin of 5.59% and a negative return on equity of 53.38%. The business had revenue of $7.26 million during the quarter, compared to analyst estimates of $13.67 million. During the same period last year, the company earned ($0.21) EPS. On average, research analysts expect that Fennec Pharmaceuticals Inc will post 0.27 earnings per share for the current year.

Wall Street Analyst Weigh In

FENC has been the subject of several research analyst reports. Wedbush reaffirmed an “outperform” rating and set a $14.00 target price (down from $16.00) on shares of Fennec Pharmaceuticals in a research note on Tuesday, August 13th. Craig Hallum dropped their price target on Fennec Pharmaceuticals from $17.00 to $15.00 and set a “buy” rating for the company in a research report on Wednesday, August 14th. Finally, HC Wainwright dropped their price target on Fennec Pharmaceuticals from $15.00 to $13.00 and set a “buy” rating for the company in a research report on Thursday, August 22nd.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.